Tirzepatide

The short answer: yes, when the compounded product contains the same dose of the same molecule at the same purity. Tirzepatide is tirzepatide.

Yes. Compounded tirzepatide is available in 2026, dispensed by state-licensed 503A pharmacies on patient-specific prescriptions.

Compounded tirzepatide is available through 503A pharmacies in 2026 when prescribed for an individual patient with documented clinical need.

Zepbound is Eli Lilly’s FDA-approved tirzepatide for chronic weight management, approved November 2023 at doses up to 15 mg weekly.

Mounjaro is Eli Lilly’s brand-name tirzepatide, FDA-approved in May 2022 for type 2 diabetes.

Switching between Mounjaro, Zepbound, and compounded tirzepatide is straightforward because the active ingredient is identical.

Compounded tirzepatide is a sterile injectable peptide that needs refrigeration at 36°F to 46°F (2°C to 8°C).

Compounded tirzepatide vials should be refrigerated between 36-46°F (2-8°C) until first use.

Most tirzepatide side effects are gastrointestinal and concentrated in the first 12-16 weeks. In SURMOUNT-1 (Jastreboff et al.